The combination statistically significantly improved overall survival, reducing the risk of death by 21% compared with chemotherapy alone. The Food and Drug Administration (FDA) has approved Keytruda ...

Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on findings from the KEYNOTE-483 trial. The Food and Drug Administration (FDA) ...

Patients with malignant pleural mesothelioma are diagnosed at advanced stages and have limited treatment options. Patients with coexpression of ERCC1 and RPM1 in tumor tissues exhibited significantly ...

Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM) in combination ...

A new research paper titled "Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable ...

VT3989, a transcriptional enhanced associate domain autopalmitoylation inhibitor, targets the Hippo pathway in mesothelioma treatment. The FDA's fast track designation aims to expedite VT3989's ...

A new research paper was published in Oncotarget's Volume 15 on June 20, 2024, entitled, "Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination ...

Combining a WT1 cancer vaccine (galinpepimut-S) with checkpoint inhibition (nivolumab) in patients with WT1-expressing diffuse pleural mesothelioma (DPM): A phase I study. This is an ASCO Meeting ...

This figure outlines diagnostic and management consensus of MMTVT, including 4 key modules: the screening, diagnosis, treatment, follow-up. (1) Screening: For those aged 60-80 (mainly), with asbestos ...

Peter Szlosarek, Professor of Medical Oncology at Queen Mary's Barts Cancer Institute, presented his team's results from the ATOMIC-Meso clinical trial in partnership with Polaris Pharmaceuticals, Inc ...